Top Tips: Cell & Gene Manufacturing Process Efficiencies - Automation, Scale up & Scale Out

Chan
Posted: 02/23/2016
Job: Editor
Company: Cold Chain IQ

The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.

In regards to the progress required behind this market in regards to process excellence, Elena Meurer, Head of Pharmaceutical and Technical Development at apceth GmbH & Co.KG sees two major routes towards improvement. For small autologous products - develop a strategy to produce everything at the patient side in the clinic, so for a closed automated system which will allow manufacturers to avoid the use of clean room. It is however not possible if the manufacturing of a cell product is lengthy due to a cell expansion phase. In this case, a simple, robust process should be developed to ensure the product’s success, as the patient material is valuable. Secondly, the adoption of allogenic manufacturing of huge batches which would allow for the cost minimisation.

Interested in learning more about this topic?
Cell and gene
Download the agenda for Cell & Gene Manufacturing 2017

The race towards commercialisation of cell and gene products has already begun. Where technology innovations are pathing the way towards the development of these products, challenges surrounding scale up and closed system processing highlight areas that need our focus so that cell and gene therapy products can be produced on an industrial scale

The Cell and Gene Therapy Manufacturing Forum is the only conference that is 100% dedicated to focusing on development ofmanufacturing processes for these products. With presentations on improving cost efficiency, innovative strategies forcommercialisation as well as closed system processing, optimised manufacturing scheduling and maintaining GMP compliance, this forum is one that is not to be missed!

One key point of focus is not only the move towards scaling up - manufacturing bigger batches of product- but also scaling out - manufacturing more batches.

In response, to this Pharma IQ spoke to Elena Meurer of apceth GmbH & Co.KG to compile this best practise guide automation scale up –and scale out for cell and gene therapies.

To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

Chan
Posted: 02/23/2016
Job: Editor
Company: Cold Chain IQ

Pharma IQ Members